Unlock instant, AI-driven research and patent intelligence for your innovation.

Ligands of adenine nucleotide translocase (ANT) and compositions and methods related thereto

a technology which is applied in the field of ligands of adenine nucleotide translocase and compositions and methods related thereto, can solve the problems of affecting the mitochondria themselves, generating highly reactive free radicals that have the potential of damaging cells and tissues, and affecting the ability of free radical mediated damage to inactivate one or more, so as to achieve the effect of facilitating or affecting treatment or preventing

Inactive Publication Date: 2006-01-05
MIGENIX CORP +1
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Altered or defective mitochondrial activity, including but not limited to failure at any step of the ETC, may result in the generation of highly reactive free radicals that have the potential of damaging cells and tissues.
These free radicals may include reactive oxygen species (ROS) such as superoxide, peroxynitrite and hydroxyl radicals, and potentially other reactive species that may be toxic to cells.
In addition to free radical mediated tissue damage, there are at least two deleterious consequences of exposure to reactive free radicals arising from mitochondrial dysfunction that adversely impact the mitochondria themselves.
First, free radical mediated damage may inactivate one or more of the myriad proteins of the ETC.
Second, free radical mediated damage may result in catastrophic mitochondrial collapse that has been termed “permeability transition” (PT) or “mitochondrial permeability transition” (MPT).
Free radical oxidative activity, may dissipate this membrane potential, thereby preventing ATP biosynthesis and halting the production of a vital biochemical energy source.
Moreover, some disease states are thought to be associated with either insufficient (e.g., cancer, autoimmune diseases) or excessive (e.g., stroke damage, AD-associated neurodegeneration) levels of apoptosis.
When, however, the integrity of the inner mitochondrial membrane is compromised, as occurs during MPT, which may accompany a disease associated with altered mitochondrial function, protons are able to bypass the conduit of Complex V without generating ATP, thereby “uncoupling” respiration because electron transfer and associated proton pumping yields no ATP.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ligands of adenine nucleotide translocase (ANT) and compositions and methods related thereto
  • Ligands of adenine nucleotide translocase (ANT) and compositions and methods related thereto
  • Ligands of adenine nucleotide translocase (ANT) and compositions and methods related thereto

Examples

Experimental program
Comparison scheme
Effect test

example 1

Synthesis of Representative Compounds

[0068] These examples illustrate the preparation of certain representative compounds.

A. General Synthesis of 3-Aryloxymethyl Analogs of Salicylic Acid

Synthesis of 3-methylsalicyclic Acid Methyl Ester, Structure 2:

[0069] A mixture of 3-methylsalicyclic acid 1 (15.2 g, 100 mmol), MeOH (300 mL), and concentrated H2SO4 (40 mL) was refluxed overnight. The excess amount of MeOH was evaporated under reduced pressure, and then the residue was diluted carefully with H2O and extracted with EtOAc twice. The combined organic layer was washed with saturated NaHCO3, brine, and dried over Na2SO4, filtered, concentrated, and the residue was purified by column chromatography on silica gel (EtOAc / hexane: 5 / 95) to give structure 2 (13.8 g, 83%) as a colorless oil.

Synthesis of structure 3:

[0070] To a solution of DMAP (561 mg, 4.59 mmol), Et3N (12.8 mL, 91.8 mmol) and AcCl (5.41 g, 68.9 mmol) in CH2Cl2 (150 mL) was added structure 2 (7.62 g, 45.9 mmol) in C...

example 2

Representative Compounds of Structure (I)

[0088]

TABLE 2(I)Cpd.R1R2R3R4R5R61—CH3—C(CH3)3—H—H—H—C(CH3)32—CH3—H—H—H—H3—CH3—H—H—C(CH3)3—H—H4—CH3—H—H—Cl—H—H5—CH3—H—H—H—Cl—Cl6—CH3—H—H—H—H7—CH3—H—H—C(CH3)2CH2CH3—H—H8—CH3—H—H—C6H5—H—H9—CH3—H—H—H—Cl—H10—CH3—H—H—H—H11—CH3—H—H—H—C(CH3)3—H12—CH3—H—H—H—H—C6H513—CH3—H—H—H—H14—H—H—H—H—H15—H—H—Br—H—H16—H—H—H—H—OCH2CH317—CH3—H—H—H18—CH3—H—H19—CH3—C(CH3)3—H—CH3—H—C(CH3)320—CH3—H—H—CH3—H—H21—H—H—H—H22—H—H—OCH323—H—H—H—H—CH2OH24—H—H—H—H25—CH3—H—C(CH3)3—H—C(CH3)326—CH3—H—H—H—H—C(CH3)327—H—H—H—H—H28—H—H—H—C(CH3)2CH2CH3—H—H29—H—H—H—H—H30—CH3—H—H—Br—H—H31—CH3—H—H—Cl—H—CH332—CH3—H—H—H—H33—CH3—H—H—H—H34—CH3—H—H—H—H35—CH3—H—H—I—H—H36—CH3—H—H—H—I—H37—CH3—H—H—CH2CH3—H—H38—CH3—H—CH3—H—CH3—CH339—CH3—H—H—H40—CH3—H—H—H—H—I41—CH3—H—H—H—Br—H42—CH3—H—CH3—H—H—F43—CH3—H—H—Cl—H—Cl44—H—H—C(CH3)3—H—H45—H—H—C(CH3)3—H—H46—H—H—C(CH3)3—H—H47—H—H—C(CH3)3—H—H48—H—H—C(CH3)3—H—H49—H—H—C(CH3)3—H—H50—H—H—C(CH3)3—H—H51—H—H—C(CH3)3—H—H52—H—H—C(CH3)3—H—H53—H—H—C(CH3)3—H—H54—H—H—C(CH3)3...

example 3

ANT Ligand Binding Assay of Representative Compounds

[0089] A competitive binding assay measuring the ability of compounds 1-73 to bind to an ANT polypeptide was performed. A modification of the procedures set forth in U.S. Ser. No. 09 / 569,327 entitled “Production of Adenine Nucleotide Translocator (ANT), Novel ANT Ligands and Screening Assays Therefor” (incorporated herein by reference) was utilized. In brief, competitive binding assays were performed using purified mitochondria from mammalian tissue or from T. ni cells infected with a baculovirus expressing ANT protein. The mitochondria were incubated with 0.5 nm of a labeled atractyloside derivative (e.g., 125I-ATR) and 20 μM of the compound to be tested or a control compound. After incubation of the mitochondria preparation with the compound and the labeled ligand, the reaction is applied to filter paper, the filter paper washed to remove non-specific binding, then dried and the bound radioactivity determined via scintillation c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
molecular weightsaaaaaaaaaa
electrochemical potentialaaaaaaaaaa
Login to View More

Abstract

Compounds which have utility in the treatment of conditions associated with altered mitochondrial function. The compounds have the following structure (I): including stereoisomers, prodrugs, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined herein. Pharmaceutical compositions containing a compound of structure (I), as well as methods relating to the use thereof, are also disclosed.

Description

CROSS-REFERENCE TO RELATED APPLICATION [0001] This application is a continuation of U.S. patent application Ser. No. 10 / 741,595 filed Dec. 19, 2003, now allowed, which application claims the benefit of U.S. Provisional Patent Application No. 60 / 435,420 filed Dec. 20, 2002, both of which applications are incorporated herein by reference in their entireties.BACKGROUND OF THE INVENTION [0002] 1. Field of the Invention [0003] The present invention relates generally to novel classes of compounds which interact with adenine nucleotide translocase (ANT), as well as to compositions and methods for using such compounds to treat conditions associated with altered mitochondrial function. [0004] 2. Description of the Related Art [0005] Mitochondria are the main energy source in cells of higher organisms, and these organelles provide direct and indirect biochemical regulation of a wide array of cellular respiratory, oxidative and metabolic processes. These include electron transport chain (ETC) ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/277C07C255/41A61K31/185A61P25/00C07C65/24C07C65/30C07C65/40C07C69/94C07D263/56C07D263/57C07D277/66C07D307/80C07D333/16C07D333/24C07D333/56C07D333/60
CPCA61K31/185C07C65/24C07C65/30C07C65/40C07C69/94C07D333/60C07D277/66C07D307/80C07D333/16C07D333/24C07D333/56C07D263/57A61P3/04A61P3/10A61P9/00A61P17/06A61P19/02A61P19/04A61P25/00A61P25/06A61P25/14A61P25/16A61P25/18A61P25/28A61P27/16A61P35/00A61P43/00
Inventor GHOSH, SOUMITRA S.PEI, YAZHONGTANG, XIAO-QINGLIRAS, SPIROSAHLIJANIAN, MICHAEL K.
Owner MIGENIX CORP